Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants

NCT01954082 is registered in ClinicalTrials.gov with NICHD Neonatal Research Network as lead sponsor.

NCT NCT01954082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01954082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Lead sponsor
NICHD Neonatal Research Network
Phase
Phase 3
Overall status
Terminated
Start date
April 17, 2014
Completion date
December 31, 2016
Enrollment
638 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

retinopathy of prematurity (rop)